UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO
SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Akcea Therapeutics, Inc.
(Name of Subject Company)
Akcea Therapeutics, Inc.
(Name of Person(s) Filing Statement)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
00972L107
(CUSIP Number of Common Stock)
Damien McDevitt
Chief Executive Officer
Akcea Therapeutics, Inc.
22 Boston Wharf Road, 9th Floor
Boston, MA 02210
(617) 207-0202
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Person(s) Filing Statement)
With copies to:
Zachary Blume
Christopher D. Comeau
Ropes & Gray LLP
Prudential Tower
800 Boylston Street
Boston, Massachusetts 02199
(617) 951-7000
| ☒ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
This Schedule 14D-9C consists of the following document related to the proposed acquisition (the “Proposed Acquisition”) of Akcea Therapeutics, Inc. (the “Company” or “Akcea”) pursuant to the terms of an Agreement and Plan of Merger (the “Merger Agreement”) among the Company, Ionis Pharmaceuticals, Inc., a Delaware corporation (“Parent”), and Parent’s wholly owned subsidiary, Avalanche Merger Sub, Inc., a Delaware corporation.
| 1) | Internal Employee FAQ, dated September 1, 2020, issued by the Company to the Employees of the Company, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference |
The item listed above was first used or made available on September 1, 2020. In addition, the information set forth under Items 1.01, 5.03, 8.01 and 9.01 of the Current Report on Form 8-K filed by the Company on August 31, 2020 (including all exhibits attached thereto) is incorporated herein by reference.
| Exhibit |
Description | |
| 99.1 | Internal Employee FAQ, dated September 1, 2020, issued by the Company to the Employees of the Company | |